Skip to main content
Sage Choice logoLink to Sage Choice
. 2011 Dec 12;9(1):79. doi: 10.1177/1479164111426971

Corrigendum

PMCID: PMC4973430  PMID: 28071939

The following article contains an error: ‘A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model’ by Tracey Gaspari, HongBin Liu, Iresha Welungoda, Yunshan Hu, Robert E Widdop, Lotte B Knudsen, Richard W Simpson and Anthony E Dear, published in Diabetes & Vascular Disease Research 2011; 8(2): 117–124, DOI: 10.1177/1479164111404257.

The following corrections apply:

Page 121, left column, the third paragraph, beginning ‘No significant change…’, should be replaced with the following text:

A small but significant decrease in body weight and trend to reduction in systolic blood pressure was noted in the liraglutide treated groups (data shown below).

Additional Figure.

Additional Figure.

Data in relation to body weight and systolic blood pressure from the four-week in vivo study.

*p<0.05, liraglutide group before treatment commenced vs liraglutide group after treatment commenced.

The authors apologize for this error.


Articles from Diabetes & Vascular Disease Research are provided here courtesy of SAGE Publications

RESOURCES